歌禮制藥-B(01672.HK)：年度總收入同比增長119.6%，研發開支達2.13億元
格隆匯3月22日丨歌禮制藥-B(01672.HK)發佈公吿，截至2021年12月31日止年度，實現收入總計人民幣7687.6萬元，同比增長119.6%。該年度集團錄得由毛損轉為毛利的轉變，錄得毛利約為人民幣3920萬元，增加約266.7%。集團的研發開支由上年度的約人民幣1.091億元增加95.5%至該年度的約人民幣2.133億元，主要由於集團持續投入研發針對新型冠狀病毒肺炎(COVID-19)及慢性乙型肝炎(CHB)功能性治癒的抗病毒候選藥物。
於2021年12月31日，集團已對三種產品進行商業化，即戈諾衞®(達諾瑞韋)、新力萊®(拉維達韋)及派羅欣®。報吿期內產生的收入包括(i)派羅欣®的推廣服務；(ii)來自合作伙伴的合作收入；及(iii)新力萊®(拉維達韋)聯合戈諾衞®(達諾瑞韋)的全口服治療方案的產品銷售。報吿期間，毛利的增加主要由於(i)派羅欣®(慢性乙肝的上市藥物)的推廣服務收入穩定增加；(ii)就派羅欣®推廣服務持續提升成本效益的策略；及(iii)來自合作伙伴的收入增加。
報吿期間及直至該公吿日期，集團已取得以下進展：(i)已自國家藥監局取得利托那韋片(100毫克薄膜衣片)的上市許可批准；(ii)已於12個歐洲國家(德國、法國、愛爾蘭、英國、西班牙、葡萄牙、意大利、比利時、波蘭、瑞典、荷蘭及丹麥)提交利托那韋片(100毫克薄膜衣片)的上市許可申請；(iii)全口服直接抗慢性丙肝(HCV)新力萊®╱戈諾衞®治療方案已列入國家醫保藥品目錄(“NRDL”)； (iv)已推進(a)一種候選藥物進入III期臨牀試驗(ASC40-rGBM-CN)，(b)一種候選藥物進入IIb期臨牀試驗(ASC22-HBV-CN)，及(c)四種候選藥物進入II期臨牀試驗(ASC42-HBV-CN、ASC40-acne-CN、ASC42-PBC-CN及ASC22-HIV-CN)；(v)集團的合作伙伴Sagimet Biosciences Inc.(前稱為3-V Biosciences, Inc.)已將一種候選藥物推進入IIb期臨牀試驗(ASC40-非酒精性脂肪性肝炎-US)；及(vi)集團已取得10項IND批准，包括：(a)自FDA取得的四項IND批准(ASC41-非酒精性脂肪性肝炎-US、ASC43F-非酒精性脂肪性肝炎-US、 ASC22-HBV-US、ASC61-Oncology-US)，及(b)自國家藥監局取得六項IND批准(ASC40-rGBM-CN、ASC40-acne-CN、ASC42-PBC-CN、ASC42-非酒精性脂肪性肝炎-CN、ASC22-HIV-CN、ASC42-HBV-CN)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
